-
1
-
-
33745786806
-
Adverse side-effects to biological agents
-
Pichler WJ. Adverse side-effects to biological agents. Allergy 2006; 61: 912-920.
-
(2006)
Allergy
, vol.61
, pp. 912-920
-
-
Pichler, W.J.1
-
2
-
-
35548983383
-
Management and preparedness for infusion and hypersensitivity reactions
-
Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. The oncologist 2007; 12: 601-9.
-
(2007)
The Oncologist
, vol.12
, pp. 601-609
-
-
Lenz, H.J.1
-
3
-
-
77950433553
-
Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions
-
Vultaggio A, Matucci A, Nencini F, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65: 657-61.
-
(2010)
Allergy
, vol.65
, pp. 657-661
-
-
Vultaggio, A.1
Matucci, A.2
Nencini, F.3
-
4
-
-
70350346904
-
Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: A cohort study of 92 patients
-
Esmailzadeh A, Yousefi P, Farhi D, et al. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatology 2009; 219: 263-7.
-
(2009)
Dermatology
, vol.219
, pp. 263-267
-
-
Esmailzadeh, A.1
Yousefi, P.2
Farhi, D.3
-
5
-
-
74149087430
-
Evénements cutanéomuqueux au cours des traitements par anti-TNF alpha: Étude observationnelle propspective de 41 cas
-
Bonnet N, Guis S, Koeppel MC, et al. Evénements cutanéomuqueux au cours des traitements par anti-TNF alpha: étude observationnelle propspective de 41 cas. Ann Dermatol Venereol 2010; 137: 12-20.
-
(2010)
Ann Dermatol Venereol
, vol.137
, pp. 12-20
-
-
Bonnet, N.1
Guis, S.2
Koeppel, M.C.3
-
6
-
-
56549098599
-
Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: A cross-sectional study
-
Davaine AC, Saraux A, Prigent S, et al. Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study. J Eur Acad Dermatol Venereol 2008; 22: 1471-7.
-
(2008)
J Eur Acad Dermatol Venereol
, vol.22
, pp. 1471-1477
-
-
Davaine, A.C.1
Saraux, A.2
Prigent, S.3
-
7
-
-
33846950349
-
Cutaneous side-effects in patients with rheumatic diseases during application of tumor necrosis factor-alpha antagonists
-
Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumor necrosis factor-alpha antagonists. Br J Dermatol 2007; 156: 486-91.
-
(2007)
Br J Dermatol
, vol.156
, pp. 486-491
-
-
Lee, H.H.1
Song, I.H.2
Friedrich, M.3
-
8
-
-
24944532440
-
Dermatological conditions during TNF-x- blocking therapy in patients with rheumatoid arthritis: A prospective study
-
Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-x- blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005; 7: 666-76.
-
(2005)
Arthritis Res Ther
, vol.7
, pp. 666-676
-
-
Flendrie, M.1
Vissers, W.H.2
Creemers, M.C.3
de Jong, E.M.4
van de Kerkhof, P.C.5
van Riel, P.L.6
-
9
-
-
0037709396
-
Atopic dermatitis-like eruption precipitated by infliximab
-
Wright RC. Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol 2003; 49: 160-1.
-
(2003)
J Am Acad Dermatol
, vol.49
, pp. 160-161
-
-
Wright, R.C.1
-
10
-
-
0033830347
-
Reduced incidence and prevalence of atopy in rheumatoid arthritis
-
Results of a case-control study
-
Hilliquin P, Allanore Y, Coste J, Renoux M, Kahan A, Menkes CJ. Reduced incidence and prevalence of atopy in rheumatoid arthritis. Results of a case-control study. Rheumatology (Oxford) 2000; 39: 1020-26.
-
(2000)
Rheumatology (Oxford)
, vol.39
, pp. 1020-1026
-
-
Hilliquin, P.1
Allanore, Y.2
Coste, J.3
Renoux, M.4
Kahan, A.5
Menkes, C.J.6
-
11
-
-
2342538439
-
Infliximab infusion reactions: Desensitizing ourselves to the danger
-
Persley KM. Infliximab infusion reactions: desensitizing ourselves to the danger. Inflamm Bowel Dis 2004; 10: 62-3.
-
(2004)
Inflamm Bowel Dis
, vol.10
, pp. 62-63
-
-
Persley, K.M.1
-
12
-
-
0038649858
-
The incidence and management of infusion reactions to infliximab: A large center experience
-
Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-24.
-
(2003)
Am J Gastroenterol
, vol.98
, pp. 1315-1324
-
-
Cheifetz, A.1
Smedley, M.2
Martin, S.3
-
15
-
-
2542637077
-
Severe anaphylactic reaction to infliximab: Successful treatment with adalimumab - report of a case
-
Stallmach A, Giese T, Schmidt C, Meuer SC, Zeuzem SS. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. Eur J Gastroenterol Hepato 2004; 16: 627-30.
-
(2004)
Eur J Gastroenterol Hepato
, vol.16
, pp. 627-630
-
-
Stallmach, A.1
Giese, T.2
Schmidt, C.3
Meuer, S.C.4
Zeuzem, S.S.5
-
16
-
-
0035007087
-
Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction
-
Puchner TC, Kugathasan S, Kelly KJ, Binion DG. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 2001; 7: 34-7.
-
(2001)
Inflamm Bowel Dis
, vol.7
, pp. 34-37
-
-
Puchner, T.C.1
Kugathasan, S.2
Kelly, K.J.3
Binion, D.G.4
-
17
-
-
0036715313
-
Cutaneous drug. eruption to infliximab: Report of 4 cases with an interface dermatitis pattern
-
Vergara G, Silvestre JF, Betlloch I, Vela P, Albares MP, Pascual JC. Cutaneous drug. eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol 2002; 138: 1258-9.
-
(2002)
Arch Dermatol
, vol.138
, pp. 1258-1259
-
-
Vergara, G.1
Silvestre, J.F.2
Betlloch, I.3
Vela, P.4
Albares, M.P.5
Pascual, J.C.6
-
18
-
-
37349003068
-
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
-
Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15.
-
(2008)
J Am Acad Dermatol
, vol.58
, pp. 106-115
-
-
Menter, A.1
Tyring, S.K.2
Gordon, K.3
-
19
-
-
36649025481
-
Injection site reactions to TNF-alpha blocking agents with positive skin tests
-
Benucci M, Manfredi M, Demoly P, Campi P. Injection site reactions to TNF-alpha blocking agents with positive skin tests. Allergy 2008; 63: 138-9.
-
(2008)
Allergy
, vol.63
, pp. 138-139
-
-
Benucci, M.1
Manfredi, M.2
Demoly, P.3
Campi, P.4
-
21
-
-
63949087636
-
Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: Report of three cases and review of literature
-
Saif MW, Peccerillo J, Potter V. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Cancer Chemother Pharmacol 2009; 63: 1017-22.
-
(2009)
Cancer Chemother Pharmacol
, vol.63
, pp. 1017-1022
-
-
Saif, M.W.1
Peccerillo, J.2
Potter, V.3
-
23
-
-
33846148701
-
For TARGET stu dy gro up. Sorafenib in advanced clear-cell renal-cell carcinoma
-
Escudier B, Eisen T, Stadler WM, et al.; For TARGET stu dy gro up. Sorafenib in advanced clear-cell renal-cell carcinoma. N Eng J Med 2007; 356: 125-34.
-
(2007)
N Eng J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
-
24
-
-
47849105015
-
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor
-
Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008; 144: 886-92.
-
(2008)
Arch Dermatol
, vol.144
, pp. 886-892
-
-
Autier, J.1
Escudier, B.2
Wechsler, J.3
Spatz, A.4
Robert, C.5
-
26
-
-
0038823848
-
Dose-dependent severe cutaneous reactions to imatinib
-
Ugurel S, Hildenbrand R, Dippel E, Hochhaus A, Schadendorf D. Dose-dependent severe cutaneous reactions to imatinib. Br J Cancer 2003; 88: 1157-9.
-
(2003)
Br J Cancer
, vol.88
, pp. 1157-1159
-
-
Ugurel, S.1
Hildenbrand, R.2
Dippel, E.3
Hochhaus, A.4
Schadendorf, D.5
-
27
-
-
0344556916
-
Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients
-
Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003; 48: 201-6.
-
(2003)
J Am Acad Dermatol
, vol.48
, pp. 201-206
-
-
Valeyrie, L.1
Bastuji-Garin, S.2
Revuz, J.3
-
28
-
-
20844441783
-
Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec)
-
Esmaeli B, Diba R, Ahmadi MA, et al. Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec). Eye 2004; 18: 760-2.
-
(2004)
Eye
, vol.18
, pp. 760-762
-
-
Esmaeli, B.1
Diba, R.2
Ahmadi, M.A.3
-
29
-
-
0842305855
-
Oedème palpébral secondaire au traitement par inhibiteur de la tyrosine kinase: Glivec®
-
Maalouf T, Angioï K, Champigneulle J, Guerci A, George JL. OEdème palpébral secondaire au traitement par inhibiteur de la tyrosine kinase: Glivec®. J Fr Ophtalmol 2004; 27: 107-9.
-
(2004)
J Fr Ophtalmol
, vol.27
, pp. 107-109
-
-
Maalouf, T.1
Angioï, K.2
Champigneulle, J.3
Guerci, A.4
George, J.L.5
-
30
-
-
0036816328
-
Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia
-
Schwarz M, Kreuzer KA, Baskaynak G, Dörken B, le Coutre P. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol 2002; 69: 254-6.
-
(2002)
Eur J Haematol
, vol.69
, pp. 254-256
-
-
Schwarz, M.1
Kreuzer, K.A.2
Baskaynak, G.3
Dörken, B.4
le Coutre, P.5
-
31
-
-
0034837552
-
Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia
-
Brouard MC, Prins C, Mach-Pascual S, Saurat JH. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. Dermatology 2001; 203: 57-9.
-
(2001)
Dermatology
, vol.203
, pp. 57-59
-
-
Brouard, M.C.1
Prins, C.2
Mach-Pascual, S.3
Saurat, J.H.4
-
32
-
-
36749075610
-
Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism
-
Vano-Galvan S, Fernandez-Guarino M, Henriquez-Santana A, De Las Heras E, Calbacho M, Jaen P. Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism. Eur J Dermatol 2007; 17: 538-9.
-
(2007)
Eur J Dermatol
, vol.17
, pp. 538-539
-
-
Vano-Galvan, S.1
Fernandez-Guarino, M.2
Henriquez-Santana, A.3
de las Heras, E.4
Calbacho, M.5
Jaen, P.6
-
33
-
-
33748745838
-
DRESS (Drug reaction with eosinophilia and systemic symptoms) après traitement par imatinib (Glivec®)
-
Le Nouail P, Viseux V, Chaby G, Billet A, Denoeux JP, Lok C. DRESS (Drug reaction with eosinophilia and systemic symptoms) après traitement par imatinib (Glivec®). Ann Dermatol Venereol 2006; 133: 686-8.
-
(2006)
Ann Dermatol Venereol
, vol.133
, pp. 686-688
-
-
le Nouail, P.1
Viseux, V.2
Chaby, G.3
Billet, A.4
Denoeux, J.P.5
Lok, C.6
-
35
-
-
0036110317
-
Stevens-Johnson syndrome after treatment with STI571: A case report
-
Hsiao LT, Chung HM, Lin JT, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol 2002; 117: 620-2.
-
(2002)
Br J Haematol
, vol.117
, pp. 620-622
-
-
Hsiao, L.T.1
Chung, H.M.2
Lin, J.T.3
-
36
-
-
0037838406
-
Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation
-
Schaich M, Schäkel K, Illmer T, Ehninger G, Bornhäuser M. Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation. Ann Hematol 2003; 82: 303-4.
-
(2003)
Ann Hematol
, vol.82
, pp. 303-304
-
-
Schaich, M.1
Schäkel, K.2
Illmer, T.3
Ehninger, G.4
Bornhäuser, M.5
-
37
-
-
14644427729
-
Cutaneous reactions to imatinib mesylate treated by topical steroid
-
Ujiie H, Shimizu T, Shimizu H. Cutaneous reactions to imatinib mesylate treated by topical steroid. Am J Hematol 2005; 78: 246.
-
(2005)
Am J Hematol
, vol.78
, pp. 246
-
-
Ujiie, H.1
Shimizu, T.2
Shimizu, H.3
-
38
-
-
33747646206
-
Desensitization to imatinib in patients with leukemia
-
Nelson RP Jr, Cornetta K, Ward KE, Ramanuja S, Fausel C, Cripe LD. Desensitization to imatinib in patients with leukemia. Ann Allergy Asthma Immunol 2006; 97: 216-22.
-
(2006)
Ann Allergy Asthma Immunol
, vol.97
, pp. 216-222
-
-
Nelson Jr., R.P.1
Cornetta, K.2
Ward, K.E.3
Ramanuja, S.4
Fausel, C.5
Cripe, L.D.6
-
39
-
-
33646562211
-
Imatinib-associated lichenoid eruption: Acitretin treatment allows maintained antineoplastic effect
-
Dalmau J, Peramiquel L, Puig L, Fernández-Figueras MT, Roé E, Alomar A. Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect. Br J Dermatol 2006; 154: 1213-6.
-
(2006)
Br J Dermatol
, vol.154
, pp. 1213-1216
-
-
Dalmau, J.1
Peramiquel, L.2
Puig, L.3
Fernández-Figueras, M.T.4
Roé, E.5
Alomar, A.6
-
40
-
-
61349131926
-
Rapid infusion of rituximab over 60 min
-
Tuthill M, Crook T, Corbet T, King J, Webb A Rapid infusion of rituximab over 60 min. Eur J Haematol 2009; 82: 322-5.
-
(2009)
Eur J Haematol
, vol.82
, pp. 322-325
-
-
Tuthill, M.1
Crook, T.2
Corbet, T.3
King, J.4
Webb, A.5
-
41
-
-
33846657588
-
Unique aspects of supportive care using monoclonal antibodies in cancer treatment
-
Dillman RO, Hendrix CS. Unique aspects of supportive care using monoclonal antibodies in cancer treatment. Support Cancer Ther 2003; 1: 38-48.
-
(2003)
Support Cancer Ther
, vol.1
, pp. 38-48
-
-
Dillman, R.O.1
Hendrix, C.S.2
-
42
-
-
50649085243
-
Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases
-
Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008; 122: 574-80.
-
(2008)
J Allergy Clin Immunol
, vol.122
, pp. 574-580
-
-
Castells, M.C.1
Tennant, N.M.2
Sloane, D.E.3
-
43
-
-
63249135067
-
Plasmapheresis therapy for rare but potentially fatal reaction to rituximab
-
Hastings D, Patel B, Torloni AS, et al. Plasmapheresis therapy for rare but potentially fatal reaction to rituximab. J Clin Apher 2009; 24: 28-31.
-
(2009)
J Clin Apher
, vol.24
, pp. 28-31
-
-
Hastings, D.1
Patel, B.2
Torloni, A.S.3
-
44
-
-
43149093805
-
Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis
-
Serarslan G, Okuyucu E, Melek I, Hakverdi S, Duman T. Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis. Mult Scler. 2008; 14: 259-61.
-
(2008)
Mult Scler
, vol.14
, pp. 259-261
-
-
Serarslan, G.1
Okuyucu, E.2
Melek, I.3
Hakverdi, S.4
Duman, T.5
-
45
-
-
84856537359
-
Evaluation d'une pratique de prise en charge des toxidermies dues a l'interferon: A propos de 15 cas
-
Poreaux C, Waton J, Cuny JF, et al. Evaluation d'une pratique de prise en charge des toxidermies dues a l'interferon: a propos de 15 cas. Ann Dermatol Vénéréol 2009; 136: s317-8.
-
(2009)
Ann Dermatol Vénéréol
, vol.136
-
-
Poreaux, C.1
Waton, J.2
Cuny, J.F.3
-
46
-
-
84856526170
-
Effets cutanéo-muqueux indésirables des cytokines et des nouvelles molécules anticancéreuses
-
In: Bessis D, Francès C, Guillot B, Guilhou JJ, eds, Manifestations dermatologiques des maladies du système hématopoïétique et oncologie dermatologique. Springer- Verlag France
-
Bessis D, Dereure O, Guillot B. Effets cutanéo-muqueux indésirables des cytokines et des nouvelles molécules anticancéreuses. In: Bessis D, Francès C, Guillot B, Guilhou JJ, eds, Dermatologie et Médecine, vol.3: Manifestations dermatologiques des maladies du système hématopoïétique et oncologie dermatologique. Springer- Verlag France, 2007: 72.1-72.18.
-
(2007)
Dermatologie Et Médecine
, vol.3
-
-
Bessis, D.1
Dereure, O.2
Guillot, B.3
-
47
-
-
73349096020
-
Omalizumabassociated anaphylactic reactions reported between January 2007 and June 2008
-
Lin RY, Rodriguez-Baez G, Bhargave GA. Omalizumabassociated anaphylactic reactions reported between January 2007 and June 2008. Ann Allergy Asthma Immunol 2009; 103: 442-5.
-
(2009)
Ann Allergy Asthma Immunol
, vol.103
, pp. 442-445
-
-
Lin, R.Y.1
Rodriguez-Baez, G.2
Bhargave, G.A.3
-
48
-
-
66149147481
-
Safety and tolerability of omalizumab
-
Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy 2009; 39: 788-97.
-
(2009)
Clin Exp Allergy
, vol.39
, pp. 788-797
-
-
Corren, J.1
Casale, T.B.2
Lanier, B.3
Buhl, R.4
Holgate, S.5
Jimenez, P.6
-
49
-
-
43549089971
-
Allergic and nonallergic delayed infusion reactions during natalizumab therapy
-
Hellwig K, Schimrigk S, Fischer M, et al. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol 2008; 65: 656-8.
-
(2008)
Arch Neurol
, vol.65
, pp. 656-658
-
-
Hellwig, K.1
Schimrigk, S.2
Fischer, M.3
-
50
-
-
34548602366
-
Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies
-
Krumbholz M, Pellkofer H, Gold R, Hoffmann LA, Hohlfeld R, Kümpfel T. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol 2007; 64: 1331-3.
-
(2007)
Arch Neurol
, vol.64
, pp. 1331-1333
-
-
Krumbholz, M.1
Pellkofer, H.2
Gold, R.3
Hoffmann, L.A.4
Hohlfeld, R.5
Kümpfel, T.6
|